| P50 | author | Reginald F. Frye | Q37370763 |
| P2093 | author name string | G R Matzke | |
| P2860 | cites work | Pharmacokinetics of nitrendipine in patients with renal failure: comparison to normal subjects | Q72383333 |
| | Acyclovir neurotoxicity following oral therapy: prevention and treatment in patients on haemodialysis | Q72436627 |
| | Decreased acetylation of isoniazid in chronic renal failure | Q72692416 |
| | Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure | Q72790127 |
| | Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease | Q72809754 |
| | Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents | Q72827801 |
| | Contrast nephrotoxicity | Q72891519 |
| | Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment | Q72894682 |
| | The Pharmacokinetics and Pharmacodynamics of Methylprednisolone in Chronic Renal Failure | Q77614186 |
| | Clinical Pharmacokinetics of N-acetylprocainamide | Q28262289 |
| | Torasemide. An update of its pharmacological properties and therapeutic efficacy | Q28299296 |
| | Neurotoxicity associated with oral acyclovir in patients undergoing dialysis | Q28317325 |
| | Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion | Q28318405 |
| | Ketorolac-induced acute renal failure | Q28319398 |
| | Effects of oral prostaglandins on indomethacin-induced renal failure in patients with cirrhosis and ascites | Q28334587 |
| | Nephrotoxicity of vancomycin, alone and with an aminoglycoside | Q28335291 |
| | 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo | Q28368376 |
| | Renal disease and use of topical non-steroidal anti-inflammatory drugs | Q28378469 |
| | Torasemide | Q29541813 |
| | Prediction of creatinine clearance from serum creatinine | Q29615603 |
| | Vancomycin- and erythromycin-induced hearing loss in humans | Q30502734 |
| | Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer | Q33364853 |
| | Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group | Q33364857 |
| | Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin | Q33429015 |
| | Carboplatin dosage: prospective evaluation of a simple formula based on renal function | Q33429552 |
| | Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum | Q33458060 |
| | Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer | Q33489855 |
| | Efficacy of area under the curve cyclosporine monitoring in renal transplantation | Q72298023 |
| | Avoiding acyclovir neurotoxicity in patients with chronic renal failure undergoing haemodialysis | Q72302890 |
| | Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency | Q72320051 |
| | Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease | Q72382639 |
| | Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney F | Q72382643 |
| | Differential effects of the degree of renal damage on p-aminohippuric acid and inulin clearances in rats | Q41327805 |
| | Mild nephrotoxicity associated with vancomycin use. | Q42198840 |
| | Risk Factors for Nephrotoxicity in Patients Treated with Aminoglycosides | Q42247725 |
| | Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. | Q42275240 |
| | Prolonged sedation due to accumulation of conjugated metabolites of midazolam | Q42276898 |
| | Impact of Vancomycin Therapeutic Drug Monitoring on Patient Care | Q42278351 |
| | Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study | Q42278871 |
| | Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination | Q42286407 |
| | NSAID nephrotoxicity revisited: acute renal failure due to parenteral ketorolac | Q42287064 |
| | The effect of misoprostol on indomethacin-induced renal dysfunction in well-compensated cirrhosis | Q42557895 |
| | Dihydrocodeine overdose treated with naloxone infusion. | Q42838576 |
| | Kinetics of drug action in disease states. XVIII. Effect of experimental renal failure on the pharmacodynamics of theophylline-induced seizures in rats | Q43619275 |
| | Alprazolam in end-stage renal disease. II. Pharmacodynamics | Q43656493 |
| | Comparison of three methods for cyclosporine area under the curve monitoring calculations. | Q43818024 |
| | Influence of renal function on the pharmacokinetics and cardiovascular effects of nisoldipine after single and multiple dosing | Q44264216 |
| | A proposal of FK506 optimal dosing in living related liver transplantations | Q44613384 |
| | (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue | Q44677601 |
| | Narcotic usage in renal failure | Q45070478 |
| | Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. | Q45103287 |
| | Nonrenal clearance and tubular load in renal failure | Q45203726 |
| | Digitalis in chronic renal insufficiency | Q46510347 |
| | Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus | Q46534931 |
| | Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study | Q46842288 |
| | Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. The influence of renal failure. | Q48092839 |
| | Kinetics of drug action in disease states. XIII. Effect of dialyzable component(s) of uremic blood on phenobarbital concentrations in rats at onset of loss of righting reflex. | Q48475862 |
| | Hepatic drug metabolism in rats with experimental chronic renal failure | Q49083971 |
| | Drug protein binding in chronic renal failure: Evaluation of nine drugs | Q49172453 |
| | A new dosing regimen in renal insufficiency: application to cephalexin | Q49301077 |
| | Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. | Q50589543 |
| | Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. | Q52272460 |
| | Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy. | Q52393812 |
| | A new simple and rapid method to monitor the renal function based on pharmacokinetic consideration of endogeneous creatinine= | Q52439236 |
| | Validity of creatinine clearance estimates in the assessment of renal function. | Q52469315 |
| | Effect of renal failure on the pharmacokinetics of acyclovir. | Q52717998 |
| | What is the evidence for once-daily aminoglycoside therapy? | Q52881617 |
| | Digitalis receptors and digoxin sensitivity in renal failure. | Q53718219 |
| | Pharmacokinetic design of digoxin dosage regimens in relation to renal function. | Q53911302 |
| | Serum alpha-1-acid glycoprotein in chronic renal failure. | Q53939711 |
| | Pharmacokinetics of abecarnil in patients with renal insufficiency. | Q53988365 |
| | Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure. | Q54179675 |
| | The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease | Q56867091 |
| | Following an initial decline, glomerular filtration rate stabilizes in heart transplant patients on chronic cyclosporine | Q57704356 |
| | Plasma creatinine, and clearance and urinary excretion of creatinine in children | Q67315260 |
| | The effects of acute and chronic uremia in rats on their hepatic microsomal enzyme activity | Q67403219 |
| | Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance | Q67781827 |
| | Failure of dietary protein and phosphate restriction to retard the rate of progression of chronic renal failure: a prospective, randomized, controlled trial | Q67873235 |
| | Iatrogenic renal disease | Q67967924 |
| | Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment | Q68249148 |
| | Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison | Q68504271 |
| | Renal handling of drugs in renal failure. I: Differential effects of uranyl nitrate- and glycerol-induced acute renal failure on renal excretion of TEAB and PAH in rats | Q68508541 |
| | Measurement of vancomycin in renally impaired patient samples using a new high-performance liquid chromatography method with vitamin B12 internal standard: comparison of high-performance liquid chromatography, emit, and fluorescence polarization imm | Q68655749 |
| | Cisplatin nephrotoxicity. | Q33490335 |
| | Sodium chloride treatment of amphotericin B nephrotoxicity. Standard of care? | Q33608492 |
| | Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring | Q34061646 |
| | Acyclovir-induced renal failure. Clinical course and histology | Q34176730 |
| | Comparison of loop diuretics in patients with chronic renal insufficiency | Q34178941 |
| | Central nervous system excitatory effects of meperidine in cancer patients | Q34249774 |
| | Renal function after acyclovir intravenous injection | Q34253537 |
| | Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient | Q34285715 |
| | A suggested approach to once‐daily aminoglycoside dosing | Q34347273 |
| | An intelligent and cost-effective computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders | Q34470498 |
| | Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs. | Q34491260 |
| | Comparative ototoxicity of ribostamycin, dactimicin, dibekacin, kanamycin, amikacin, tobramycin, gentamicin, sisomicin and netilmicin in the inner ear of guinea pigs | Q34644823 |
| | Furosemide kinetics in renal failure | Q34710281 |
| | Ibuprofen as an over-the-counter drug: is there a risk for renal injury? | Q34730262 |
| | Dihydrocodeine narcosis in renal failure | Q34990567 |
| | Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients | Q35115039 |
| | Foscarnet alters antidiuretic hormone-mediated transport | Q35118306 |
| | Therapeutic implications associated with renal studies of nabumetone | Q35639666 |
| | Clinical pharmacokinetics of antibiotics in patients with impaired renal function | Q35981469 |
| | The human hepatic cytochromes P450 involved in drug metabolism | Q36258518 |
| | Chronic renal failure: pathophysiology | Q36509400 |
| | Clinical pharmacology of loop diuretics | Q36663863 |
| | The efficacy of diuretics in acute and chronic renal failure. Focus on torasemide | Q36663981 |
| | Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency | Q36756826 |
| | The Effect of Renal Failure on Hepatic Drug Clearance | Q36884131 |
| | Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections | Q37362467 |
| | An updated comparison of drug dosing methods. Part IV: Vancomycin | Q37742573 |
| | Angiotensin-converting enzyme inhibitor-induced renal failure: causes, consequences, and diagnostic uses | Q37805396 |
| | Management of cytomegalovirus disease with antiviral drugs | Q37897944 |
| | Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part I). | Q37944770 |
| | Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II). | Q37950599 |
| | Nonsteroidal anti-inflammatory drug nephrotoxicity. Should we be concerned? | Q38140809 |
| | Renal disease and drug metabolism: an overview | Q38593719 |
| | Aminoglycoside-induced hearing loss in humans | Q38676819 |
| | Reduced β-adrenoceptor sensitivity in the elderly | Q39256290 |
| | A simple method of estimating progression of chronic renal failure | Q39413560 |
| | Ototoxicity and nephrotoxicity of gentamicin vs netilmicin in patients with serious infections. A randomized clinical trial | Q39510044 |
| | Experience with a once-daily aminoglycoside program administered to 2,184 adult patients | Q39779327 |
| | Resistance to loop diuretics. Why it happens and what to do about it. | Q39834916 |
| | The sodium-potassium adenosine triphosphatase: pharmacological, physiological and biochemical aspects | Q39934585 |
| | On the meaning of the intact nephron hypothesis | Q40010343 |
| | Consequences of renal insufficiency on the hepatic clearance of some drugs | Q40094963 |
| | Clinical pharmacokinetics of acyclovir | Q40149131 |
| | Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections | Q40395218 |
| | The nephrotoxicity of FK506 as compared with cyclosporine | Q40397728 |
| | Strategies to prevent nephrotoxicity of anticancer drugs | Q40424414 |
| | Evaluation of the renal effects of calcium antagonists. | Q40443355 |
| | Amphotericin B Toxicity Reduced by Administration in Fat Emulsion | Q40471190 |
| | Recent Advances: the Cytochrome P450 Enzymes | Q40475823 |
| | Glycopeptides and nephrotoxicity | Q40495778 |
| | Hypertension in diabetic patients: an update of interventional studies to preserve renal function | Q40526153 |
| | Dosing of antihypertensive medications in patients with renal insufficiency | Q40526159 |
| | Selected aspects of ACE inhibitor therapy for patients with renal disease: impact on proteinuria, lipids and potassium | Q40526165 |
| | Non-steroidal anti-inflammatory drugs and renal function. | Q40544420 |
| | Antibiotic-related nephrotoxicity. | Q40555628 |
| | A review of the use of chemoprotectants in cancer chemotherapy | Q40563060 |
| | Gastrointestinal parameters that influence oral medications | Q40618341 |
| | Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. | Q40691752 |
| | Nephrotoxicity of amphotericin B. | Q40693938 |
| | Etoposide dosage and pharmacodynamics | Q40694372 |
| | Effect of drugs on the immature kidney | Q40708058 |
| | Area-under-the-curve versus trough level monitoring of cyclosporine concentration: critical assessment of dosage adjustment practices and measurement of clinical outcome | Q40721607 |
| | Effect of renal failure on drug metabolism by the liver | Q40722431 |
| | Cost considerations in therapeutic drug monitoring of aminoglycosides | Q40730362 |
| | A concurrent audit of high digoxin plasma levels | Q40733359 |
| | Community-acquired acute renal failure | Q40752134 |
| | Renal complications of nonsteroidal anti-inflammatory drugs | Q40775893 |
| | Newer insights into cisplatin nephrotoxicity | Q40813475 |
| | Role of phosphate retention in the progression of renal failure | Q40820402 |
| | Optimization of cyclosporine therapy. | Q40834859 |
| | Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin | Q40848346 |
| | Clinical importance of hepatic cytochrome P450 in drug metabolism | Q40923015 |
| | Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. | Q40962168 |
| | Cisplatin-based chemotherapy in renal transplant recipients. A case report and a review of the literature | Q40986988 |
| | Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis | Q40988370 |
| | Liposomal and lipid-based formulations of amphotericin B. | Q40997566 |
| | Nonrenal toxicities of acetaminophen, aspirin, and nonsteroidal anti-inflammatory agents. | Q41008399 |
| | Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group | Q41134203 |
| | Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel blocker | Q68854971 |
| | Studies of risk factors for aminoglycoside nephrotoxicity | Q68921221 |
| | Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial | Q69276633 |
| | What is the cost of nephrotoxicity associated with aminoglycosides? | Q69462800 |
| | A model for predicting nephrotoxicity in patients treated with aminoglycosides | Q69493303 |
| | Disposition of guanadrel in subjects with normal and impaired renal function | Q69600527 |
| | Dosing of contrast material to prevent contrast nephropathy in patients with renal disease | Q69623920 |
| | What do we really know about contrast medium-induced acute renal failure? | Q69666138 |
| | Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity | Q69738063 |
| | Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure | Q69749403 |
| | Disposition of minoxidil in patients with various degrees of renal function | Q69786682 |
| | Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function | Q69842141 |
| | Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster | Q69881939 |
| | Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients | Q69882555 |
| | The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group | Q70513402 |
| | Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration | Q70555080 |
| | Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media | Q70761074 |
| | Assay of vancomycin by fluorescence polarisation immunoassay and EMIT in patients with renal failure | Q70789496 |
| | Renal function and therapeutic concentrations of phenytoin | Q70789815 |
| | Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients--importance of trough level as a practical indicator | Q70822765 |
| | Falsely elevated serum vancomycin concentrations in hemodialysis patients | Q70856905 |
| | Predicting etoposide toxicity: relationship to organ function and protein binding | Q70891308 |
| | Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group | Q70989850 |
| | Ampicillin and cephalexin in renal insufficiency | Q71098386 |
| | Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial | Q71181634 |
| | Accurate measurement of impaired glomerular filtration using single-dose oral cimetidine | Q71181640 |
| | Rationale for monitoring free drug levels | Q71295370 |
| | Effects of diet and antihypertensive therapy on creatinine clearance and serum creatinine concentration in the Modification of Diet in Renal Disease Study | Q71305708 |
| | Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs | Q71380075 |
| | Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients | Q71396788 |
| | Effect of acute renal failure on neurotoxicity of cimetidine in rats | Q71485755 |
| | Metabolism of drugs by the kidney | Q71485848 |
| | Vancomycin-resistant enterococci | Q71501436 |
| | Influence of range of renal function and liver disease on predictability of creatinine clearance | Q71509238 |
| | Effect of calcium channel blockers on graft outcome in cyclosporine-treated renal allograft recipients | Q71544428 |
| | FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects | Q71612062 |
| | Nephrotoxicity of immunosuppressive drugs | Q71672075 |
| | Acute renal failure with amphotericin B in lipid emulsion | Q71697443 |
| | Anaphylactic reaction to liposomal amphotericin B in children | Q71697448 |
| | The nephrotoxic potential of netilmicin as determined in a rat model | Q72000549 |
| | Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application | Q72154569 |
| | Long-term effects of antihypertensive agents on proteinuria and renal function | Q72231528 |
| | Risk of radiocontrast nephropathy in patients with and without diabetes mellitus | Q72290136 |
| | Renal structure and function effects after low dose cyclosporine in psoriasis patients: a preliminary report | Q72295381 |
| P433 | issue | 3 | |
| P921 | main subject | renal toxicity | Q110802455 |
| P304 | page(s) | 205-231 | |
| P577 | publication date | 1997-03-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity | |
| P478 | volume | 16 | |